Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Year: 2017
Type: article
Study design: Clinical Trial
Abstract: = .0023), and similar with Rd18 (62.3 months). In patients achieving complete or very good partial responses, Rd continuous had an ≈30-month longer median time to next treatment vs Rd18 (69.5 vs 39.9 months). Over half of all patients who received second-line treatment were given a bortezomib-based therapy. Second-line outcomes were improved in patients receiving bortezomib after Rd continuous and Rd18 vs after MPT. No new safety concerns, including risk for secondary malignancies, were observed. Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible NDMM. This trial was registered at www.clinicaltrials.gov as #NCT00689936 and EudraCT as 2007-004823-39.
Source: Blood
Authors: Thierry Facon, Meletios A. Dimopoulos, Angela Dispenzieri, John V. Catalano, Andrew Belch, Michele Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie D. Cavenagh, Catarina Geraldes, Je-Jung Lee, Christine Chen, Albert Oriol, Javier De La Rubia, Darrell White, Daniel Binder, Jin Lu, Kenneth C. Anderson, Philippe Moreau, Michel Attal, Aurore Perrot, Bertrand Arnulf, Lugui Qiu, Murielle Roussel, Eileen Boyle, Salomon Manier, Mohamad Mohty, Herve Avet-Loiseau, Xavier Leleu, Annette Ervin-Haynes, Guang Chen, Vanessa Houck, Lotfi Benboubker, Cyrille Hulin
Institutions: Hôpital Claude Huriez, National and Kapodistrian University of Athens, Mayo Clinic, Frankston Hospital, Monash University, Cross Cancer Institute, University of Bologna, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", University of Tübingen, Wilhelminen Hospital, University of Calgary, Centre Hospitalier de la Côte Basque, Universitair Ziekenhuis Leuven, National Health Service, Barts Health NHS Trust, Unidade Local de Saúde de Coimbra, Chonnam National University Hwasun Hospital, Princess Margaret Cancer Centre, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, Hospital Universitario Doctor Peset, Queen Elizabeth II Health Sciences Centre, Kantonsspital Winterthur, Peking University People's Hospital, Dana-Farber Cancer Institute, Université de Nantes, Nantes Université, Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Régional et Universitaire de Nancy, Université de Lorraine, Hôpital Saint-Louis, Chinese Academy of Medical Sciences & Peking Union Medical College, Hôpital Saint-Antoine, Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Inserm, Centre Hospitalier Universitaire de Poitiers, Celgene (United States), Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Centre Hospitalier Universitaire de Bordeaux
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Celgene, National Cancer Institute
Award: G1016754749
OpenAlex ID: W2769593282